Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours?

Mortara, Lorenzo; Benest, Andrew V; Bates, David O; Noonan, Douglas M

Abstract

Tumours elicit a number of mechanisms to induce a reprogramming of innate and adaptive immune cells to their advantage, inducing a pro-angiogenic phenotype. Investigation of these events is now leading to the identification of specific myeloid and lymphoid cell-targeted therapies, as well as of unexplored off-target activities of clinically relevant chemotherapeutic and metabolic drugs. It is also leading to an enhanced understanding of the interplay between angiogenesis and the immune system, and the value of novel co-targeting approaches using both immunotherapy and anti-angiogenic therapy. Here, we review recently identified mechanisms and potential pharmacological approaches targeting the crosstalk between cancer cells and the host immune system, providing an overview on novel therapeutic opportunities linking immuno-oncology and anti-angiogenic therapy.

• Journal Article Type: Article
• Acceptance Date: Jun 6, 2017
• Online Publication Date: Jun 14, 2017
• Publication Date: 2017-08
• Deposit Date: Apr 19, 2020
• Journal: Current Opinion in Pharmacology
• Print ISSN: 1471-4892
• Electronic ISSN: 1471-4973
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 35
• Pages: 66-74
• DOI: https://doi.org/10.1016/j.coph.2017.05.009
• Public URL: https://nottingham-repository.worktribe.com/output/2572142
• Publisher URL: https://www.sciencedirect.com/science/article/abs/pii/S1471489217300516
• Additional Information: This article is maintained by: Elsevier; Article Title: Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours?; Journal Title: Current Opinion in Pharmacology; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.coph.2017.05.009; Content Type: article; Copyright: © 2017 Elsevier Ltd. All rights reserved.